Susoctocog alfa - Shire

Drug Profile

Susoctocog alfa - Shire

Alternative Names: B-Domain deleted recombinant porcine factor VIII (OBI-1); BAX 802; BAX801; Factor VIII - Ipsen; FVIII - Ipsen; OBI-1; Obizur; PFVIII; Porcine FVIII; Recombinant porcine factor VIII - Inspiration/Ipsen; RpfVIII

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University
  • Developer Baxalta; Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 24 Jun 2016 Baxalta plans a phase III trial for Haemophilia A in United Kingdom (UKCRN30415)
  • 15 Jun 2016 Baxalta initiates enrolment in a phase III trial for Haemophilia A in Spain (EudraCT2015-005521-39)
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top